EndoArt® Artificial Corneal Endothelial Implant
- Indication
- Corneal endothelial dysfunction causing chronic corneal edema; suitable for complex cases including failed traditional grafts, viral keratitis sequelae, glaucoma, and high-risk patients
- Manufacturer
- EyeYon Medical (Israel)
- Lecheng Status
- Multiple surgeries completed (May 2026) at Hainan Optometry Hospital
- Available At
- 海南眼视光眼科医院 (温州医科大学附属眼视光医院)
- Regulatory Status
- FDA: Not yet approved; EMA: Approved (CE marked); NMPA: Not yet approved in mainland China
Common Questions
Who is eligible for this treatment?
Patients with confirmed indication and a treating physician referral. International patients need a medical visa (M visa).
How can I access this treatment in Lecheng?
Contact the hospital listed in the quick facts section. International patients can use medical agents or contact the hospital directly.
What is the cost of treatment?
Costs vary by treatment protocol and length of stay. Please contact the hospital for accurate pricing. International insurance may be accepted.
Indication: Corneal endothelial dysfunction causing chronic corneal edema; suitable for complex cases including failed traditional grafts, viral keratitis sequelae, glaucoma, and high-risk patients
Manufacturer: EyeYon Medical (Israel)
Innovative synthetic corneal endothelial implant addressing the critical shortage of donor corneas in China. Unlike traditional donor grafts, it avoids immune rejection, eliminates viral transmission risk, has no endothelial cell rejection issues, and is available on-demand without waiting for donors. Four complex patients were successfully treated in the first batch.
Sources & Citations
- hainanlecheng.com · accessed 2026-07-03